The biomedical science of the 21st century is bringing us face to face with possibilities that no previous generation had ever encountered. The challenge is not merely to develop safe and effective therapies. It is also to ensure that scientific progress is accompanied by appropriate rules, transparency, and social consensus.
Anti-aging has now become one of the most widely discussed fields in biomedicine. Scientists are investigating ways to eliminate senescent cells, restore epigenetic mechanisms to a more youthful state, and enhance the body’s natural repair processes. However, despite the impressive announcements and advances, there is currently no therapy capable of reversing or halting human aging, as the gap between laboratory findings and clinical application remains substantial.
Scientists are correcting genes responsible for serious diseases, reprogramming cells so that they regain “youthful” characteristics, and developing therapies that harness the body’s own cells to combat cancer. This progress generates considerable expectations, but also raises new questions regarding the precise boundaries of human intervention in life.
Gene therapy represents one of the most significant achievements of modern medicine. Unlike conventional therapies, which primarily address symptoms, gene-based interventions target the genetic cause of disease itself. CRISPR gene-editing technology has opened new avenues for conditions that were previously considered incurable. At the same time, even more precise techniques have been developed, such as base editing, which enables the alteration of a single “letter” of the genetic code without causing a break in the DNA. In 2023, the first therapy based on CRISPR technology was approved for patients with sickle cell disease, while technologies such as base editing and prime editing are already being evaluated in clinical trials.
At the same time, cell therapies are transforming the way certain forms of cancer are treated. A prominent example is CAR-T cell therapy, in which a patient’s own cells are modified in the laboratory so that they can recognize and eliminate cancer cells. In several cases, the results have been remarkable, leading to long-term remissions in patients who had exhausted other therapeutic options.
Equally significant is the progress made in cellular reprogramming. The ability to transform a mature cell into a stem cell opened the way for regenerative medicine and the restoration of damaged tissues. In recent years, the concept of partial cellular reprogramming has emerged, whereby cells do not fully return to an embryonic state but regain certain characteristics associated with younger cells. Experimental studies have shown that the transient activation of Yamanaka factors can improve tissue function and reverse certain epigenetic markers of aging in animal models.
These technologies, however, bring not only hope but also responsibility. Particularly controversial is the prospect of genetic interventions in human embryos. In theory, such interventions could prevent the transmission of serious hereditary diseases to future generations. At the same time, however, they raise the fundamental question of where treatment ends and “human enhancement” begins. The case of the genetically modified babies announced in China in 2018 highlighted precisely this dilemma. The scientific community responded strongly, as the technology had been used without an adequate ethical and regulatory framework.
To date, there is no universal, binding global regulatory framework governing the genetic modification of the human germline. The risks remain real. Although newer techniques promise greater precision, their long-term consequences have not yet been fully elucidated. Unintended genetic alterations, unforeseen effects on other genes, and unknown consequences emerging decades after an intervention continue to concern scientists. In cellular reprogramming, the same biological plasticity that enables tissue regeneration may, if not completely controlled, increase the risk of malignant transformation. In the case of embryos, moreover, a potential error could be transmitted to subsequent generations.